
Overview
Antlia Bioscience Europe is developing novel long-acting therapeutics that target chronic cardiometabolic diseases.
Financials
Revenue history
Filing timeliness
Financial statements were filed on time, on average 8 days early.
- 202513/07/2026
- 202430/06/2025
- 202308/07/2024
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Development of long-acting therapies
- Therapies for cardiometabolic diseases
Websites
- antliabio.comAntlia Bioscience, Inc.
Authorized Representatives
Manner of representation
If the board of directors consists of two or more persons, joint action by two directors or by one director together with a commercial proxy is required to make declarations on behalf of the company. If the board of directors consists of one person, the sole director is entitled to represent the company independently.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2023-03-24.
15 1050 1344 1000 0090 3293 2866
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Meritro sp. z o.o. | $0.05 | meritro.com |
FAQ
Last updated: 2026-07-16